行情

NVRO

NVRO

Nevro
NYSE

实时行情|Nasdaq Last Sale

89.91
+0.60
+0.67%
已收盘, 16:46 09/20 EDT
开盘
89.28
昨收
89.31
最高
90.06
最低
88.91
成交量
37.47万
成交额
--
52周最高
91.60
52周最低
34.75
市值
27.77亿
市盈率(TTM)
-29.4121
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVRO 新闻

  • The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
  • Benzinga.09/13 11:40
  • Charting a bull-flag breakout, S&P 500 knifes within view of record high (3,028)
  • marketwatch.com.09/12 11:57
  • The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
  • Benzinga.09/12 11:38
  • Why Is Nevro (NVRO) Up 37.7% Since Last Earnings Report?
  • Zacks.09/07 14:30

更多

所属板块

医疗设备、用品及经销
+0.15%
医疗设备和用品
-0.22%

热门股票

名称
价格
涨跌幅

NVRO 简况

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
展开

Webull提供Nevro Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。